Allogene Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, with headquarters in South San Francisco, California. The company focuses on allogeneic CAR T-cell therapies, meaning “off-the-shelf” cell therapies made from donor cells rather than the patient’s own cells. Its strategic focus is primarily oncology, with an expanding interest in autoimmune disease, placing Allogene in one of the most scientifically ambitious areas of modern immuno-oncology. ([ir.allogene.com](https://ir.allogene.com/?utm_source=openai)) Founded in 2017, Allogene was built around deep cell-therapy and clinical-development expertise. The company does not yet have an approved commercial product and remains a clinical-stage biotech, which means revenue generation is still limited and value creation depends heavily on clinical execution, regulatory progress, and the strength of its balance sheet. The underlying investment case is tied to whether a standardized allogeneic CAR T platform can overcome some of the structural limitations of autologous CAR-T therapies, especially around manufacturing time, logistics, and access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000051/allo-20241231x10k.pdf?utm_source=openai)) Allogene’s pipeline centers on cema-cel (cemacabtagene ansegedleucel) and several additional allogeneic product candidates targeting different hematologic cancers and autoimmune indications. The company’s core thesis is that an “off-the-shelf” CAR T platform could deliver faster availability, more predictable manufacturing, and potentially more scalable economics than patient-specific cell therapies. From a competitive standpoint, Allogene operates in a crowded and highly innovative field that includes large pharmaceutical companies and specialized biotech peers pursuing CAR-T, engineered cell therapies, and next-generation immunology approaches. Its differentiation lies in being one of the more focused pure-play developers of allogeneic CAR-T technology. ([ir.allogene.com](https://ir.allogene.com/?utm_source=openai)) Geographically, the business is centered in the United States, although the company is extending trial activity and collaboration footprints beyond its home market. Recent highlights include a public equity offering announced in April 2026, expansion of the pivotal ALPHA3 trial to South Korea and Australia, and a stream of clinical and financial updates in 2026 as management positions the year as a key inflection period. For investors, Allogene remains a high-risk, high-upside development-stage biotech story on Nasdaq, with the share performance likely to remain highly sensitive to clinical readouts, cash runway, and execution against its allogeneic CAR-T roadmap. ([ir.allogene.com](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-pricing-public-offering-common-0?utm_source=openai))